{"id":"W2891207456","doi":"10.1200/jco.2017.35.15_suppl.4007","title":"Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Gemcitabine; Erlotinib; Capecitabine; Internal medicine; Pancreatic cancer; Adenocarcinoma; Gastroenterology; Stage (stratigraphy); Randomized controlled trial; Chemotherapy; Oncology; Cancer; Colorectal cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003536212,0.001765915,0.001827758,0.0005612385,0.0003540097,0.0005767508,0.0009733276,0.00159744,0.007051989],"category_scores_gemma":[0.00306326,0.0007181862,0.001960859,0.000401616,0.0009668275,0.0006721065,0.0004661781,0.002754709,0.001190304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001005085,"about_ca_system_score_gemma":0.001644603,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008118149,"about_ca_topic_score_gemma":0.002329405,"domain_scores_codex":[0.9982469,0.001330112,0.0000732167,0.000109563,0.00009611899,0.000144081],"domain_scores_gemma":[0.9978989,0.0007134814,0.0005437704,0.0001709762,0.000101279,0.0005715438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9482754,0.01739544,0.003265477,0.0002822266,0.0007131401,0.00007786207,0.00006325242,0.0008394033,0.004336199,0.00007502791,0.002409075,0.0222674],"study_design_scores_gemma":[0.7945459,0.1957953,0.005743363,0.0000293224,0.0006495481,0.00008725778,0.00001842883,0.0004546304,0.001069433,0.0001263127,0.001465651,0.00001490246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779057,0.001679735,0.0008546465,0.001259734,0.0002480166,0.01085302,0.004114255,0.0001303219,0.002954467],"genre_scores_gemma":[0.9643211,0.00161256,0.004602414,0.002077941,0.0004108415,0.01568498,0.006753786,0.0000630472,0.004473431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007051989,"threshold_uncertainty_score":0.02359122,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2280239315380705,"score_gpt":0.5543225874790554,"score_spread":0.3262986559409848,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}